Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators.
Pinkerton AB, Cube RV, Hutchinson JH, James JK, Gardner MF, Rowe BA, Schaffhauser H, Rodriguez DE, Campbell UC, Daggett LP, Vernier JM. Pinkerton AB, et al. Among authors: gardner mf. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1565-71. doi: 10.1016/j.bmcl.2005.01.077. Bioorg Med Chem Lett. 2005. PMID: 15745798
3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2).
Cube RV, Vernier JM, Hutchinson JH, Gardner MF, James JK, Rowe BA, Schaffhauser H, Daggett L, Pinkerton AB. Cube RV, et al. Among authors: gardner mf. Bioorg Med Chem Lett. 2005 May 2;15(9):2389-93. doi: 10.1016/j.bmcl.2005.02.078. Bioorg Med Chem Lett. 2005. PMID: 15837331
Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.
Govek SP, Bonnefous C, Hutchinson JH, Kamenecka T, McQuiston J, Pracitto R, Zhao LX, Gardner MF, James JK, Daggett LP, Rowe BA, Schaffhauser H, Bristow LJ, Campbell UC, Rodriguez DE, Vernier JM. Govek SP, et al. Among authors: gardner mf. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4068-72. doi: 10.1016/j.bmcl.2005.06.017. Bioorg Med Chem Lett. 2005. PMID: 16005222
Influence of acid surrogates toward potency of VLA-4 antagonist.
Venkatraman S, Lim J, Cramer M, Gardner MF, James J, Alves K, Lingham RB, Mumford RA, Munoz B. Venkatraman S, et al. Among authors: gardner mf. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4053-6. doi: 10.1016/j.bmcl.2005.06.034. Bioorg Med Chem Lett. 2005. PMID: 16039122
Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists.
Reger TS, Zunic J, Stock N, Wang B, Smith ND, Munoz B, Green MD, Gardner MF, James JP, Chen W, Alves K, Si Q, Treonze KM, Lingham RB, Mumford RA. Reger TS, et al. Among authors: gardner mf. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1173-6. doi: 10.1016/j.bmcl.2009.12.009. Epub 2009 Dec 4. Bioorg Med Chem Lett. 2010. PMID: 20022493
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, Insko DE, Ator MA, Apuy JL, Faraoni R, Dorsey BD, Williams M, Bhagwat SS, Holladay MW. James J, et al. Among authors: gardner mf. Mol Cancer Ther. 2012 Apr;11(4):930-41. doi: 10.1158/1535-7163.MCT-11-0645. Epub 2012 Feb 7. Mol Cancer Ther. 2012. PMID: 22319199
46 results